[Mechanisms of effects of adenosine and dopamine on modification of synapses in striato-nigral and striato-pallidal neurons].
On the basis of earlier suggested unitary mechanism of synaptic plasticity opposite effects of adenosine and dopamine on the cAMP concentration in striatal spinal cells can emphasize the well known antagonistic interactions between A2A and D2 receptors on striatopallidal cells and between A1 and D1 receptors on striatonigral cells. This is due to that both the dopamine agonist and adenosine antagonist must promote the induction of long-term potentiation/depression of efficacy of excitatory cortical inputs to striatopallidal/striatonigral cells. This modification must lead to synergistic disinhibition of thalamic cells via "direct" and "indirect" pathways through basal ganglia and subsequent strengthening of motor activity.
Sil'kis
I G
IG
Institute of Higher Nervous Activity and Neurophysiology of the Russian Acad. Sci., Russia, 117865, Moscow, Butlerov St., 5a.
D000241:Adenosine / Q000502:physiology*; D000818:Animals; D004298:Dopamine / Q000502:physiology*; D018491:Dopamine Agonists / Q000494:pharmacology / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D005917:Globus Pallidus / Q000502:physiology* / Q000648:ultrastructure; D006816:Huntington Disease / Q000188:drug therapy / Q000503:physiopathology; D009043:Motor Activity / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D043705:Receptor, Adenosine A2A; D017447:Receptors, Dopamine D1 / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000502:physiology; D018047:Receptors, Purinergic P1 / Q000502:physiology; D013378:Substantia Nigra / Q000502:physiology* / Q000648:ultrastructure; D013569:Synapses / Q000502:physiology*; D009435:Synaptic Transmission
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D043705:Receptor, Adenosine A2A; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D018047:Receptors, Purinergic P1; D000241:Adenosine; D004298:Dopamine